U.S. Bioreactors Market Size & Share 2024 to 2032

U.S. Bioreactors Market Size

U.S. Bioreactors Market size was valued at around USD 3.8 billion in 2023 and is estimated to grow at 11% CAGR from 2024 to 2032. A bioreactor is a device or vessel that provides a controlled environment for the cultivation of organisms such as bacteria, yeast, or animal cells, or for enzymatic or chemical reactions involving these organisms. Bioreactors are utilized in various industries, including biotechnology, pharmaceuticals, and food production, to produce products such as proteins, vaccines, enzymes, biofuels, and other bio-based materials.

The growing demand for biopharmaceuticals in the U.S., along with advancements in bioreactor technology, is driving the market's expansion. Innovations like single-use bioreactors offer cost-effectiveness and process efficiency, attracting biopharmaceutical manufacturers who seek streamlined production processes. For example, in October 2021, Waters Corporation and Sartorius AG announced a strategic collaboration aimed at providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data.
 

This initiative was designed to enhance the speed and accuracy of biopharmaceutical process development. The partnership involved integrating Waters Corporation's BioAccord LC-MS System with Sartorius AG's Ambr multi-parallel bioreactor systems. This integration delivered comprehensive mass spectral information on drug substances, related analytes, and cell culture media, significantly accelerating and improving the accuracy of tasks ranging from clone selection to bioprocess optimization.
 

Additionally, the rapid growth of the biotechnology sector, coupled with supportive government policies and stringent regulatory standards, further drives market growth. As a result, the market is experiencing a significant surge, stimulated by increased demand, technological advancements, and expanding sectors, establishing it as a critical component in the biopharmaceutical and biotechnology industries.
 

U.S. Bioreactors Market Trends

• The shift towards single-use bioreactors, which offer advantages such as reduced risk of cross-contamination, lower capital investment, and greater flexibility, is expected to significantly boost market growth. These features make single-use bioreactors particularly attractive for small-scale and multiproduct manufacturing facilities.
   
• Additionally, advancements in bioreactor technology, such as the integration of automation and real-time monitoring systems, are enhancing process efficiency and product quality.
   
• Furthermore, the escalating demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and cell and gene therapies is a prominent trend. Given the complex cell culture processes these therapies entail, the market for advanced bioreactors has witnessed a notable upswing.
   

U.S. Bioreactors Market Analysis

Based on product type, the market is bifurcated into single-use and reusable. The reusable segment dominated the market with the largest revenue of USD 2.8 billion in 2023.
 

• Reusable bioreactors are recognized for their cost-effectiveness in large-scale production. Unlike single-use bioreactors, which need to be replaced after each production run, reusable bioreactors can be sterilized and reused, resulting in significant long-term cost savings. This is particularly advantageous in industries such as biopharmaceuticals, where large product batches are necessary.
   
• Additionally, these bioreactors are valued for their robustness and ability to handle a wide range of operational conditions, making them suitable for complex and high-yield processes. They are also beneficial for processes that require specific materials or configurations not available in single-use systems.

Learn more about the key segments shaping this market

Download Free PDF

Based on cell, the U.S. bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and other cells. The mammalian cells segment dominated the market and was valued at USD 3 billion in 2023.
 

• Mammalian cells are sensitive to environmental changes, including variations in temperature, pH, oxygen levels, and nutrient supply. Bioreactors provide a controlled environment where these parameters can be meticulously regulated, ensuring optimal cell growth and productivity.
   
• Furthermore, bioreactors facilitate the implementation of advanced monitoring and automation technologies, enhancing process consistency and minimizing the risk of contamination.
   

Based on molecule, the U.S. bioreactors market is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and other molecules. The vaccines segment held the largest revenue of USD 1.9 billion in 2023.
 

• Bioreactors provide a controlled environment essential for the large-scale cultivation of cells, which are crucial for producing viral particles and recombinant proteins used in vaccines. This controlled setting ensures optimal conditions for cell growth, thereby maximizing yield and quality.
   
• Additionally, bioreactor systems are highly adaptable, accommodating various production processes, including live-attenuated, inactivated, and subunit vaccines.
   

Based on usage, the U.S. bioreactors market is bifurcated into developmental, pre-clinical & clinical, and commercial production. The commercial production segment held the largest revenue of USD 3 billion in 2023.
 

• The growing demand for biologic therapies, driven by advancements in personalized medicine and the increasing prevalence of chronic diseases, necessitates efficient and scalable production methods that bioreactors can provide.
   
• Additionally, the trend toward biosimilars, which are highly similar versions of existing biologic drugs, has intensified the need for cost-effective production processes. Bioreactors facilitate this need, particularly through economies of scale.
   

Based on size, the U.S. bioreactors market is segmented into less than 500L, 501-5,000L, and more than 5,000L. The 501-5,000L segment held the largest revenue of USD 1.5 billion in 2023.
 

• Bioreactors  within the 501-5,000L commercial production range provide a strategic balance between scalability and operational efficiency. The increasing demand for flexible production capabilities, particularly for biologics such as monoclonal antibodies, vaccines, and therapeutic proteins, serves as a primary driver.
   
• These bioreactors  are well-suited for producing quantities adequate for clinical trials and initial market release, enabling companies to scale up or down as necessary without substantial infrastructure modifications.
   

Based on material, the U.S. bioreactors market is segmented into stainless steel, glass, and single-use. The stainless steel segment is anticipated to account for the largest revenue of USD 5.5 billion by 2032.
 

• Stainless steel bioreactors are distinguished by their durability and robustness, making them ideal for extended use and high-volume production. Unlike disposable systems, these bioreactors can endure rigorous cleaning and sterilization processes, such as steam-in-place (SIP) and clean-in-place (CIP), which are essential for maintaining stringent aseptic conditions.
   
• Furthermore, stainless steel bioreactors are notable for their capacity to withstand the high pressures and temperatures required for certain biochemical reactions and large-scale fermentations.
   

Based on end-use, the U.S. bioreactors market is segmented into R&D organizations, biopharma manufacturers, and contract manufacturing organizations. The biopharma manufacturers segment dominated the market with the largest revenue of USD 1.7 billion in 2023 and is expected to grow at a lucrative CAGR over the forecast period.
 

• The increasing demand for biologics, which are complex and require advanced manufacturing processes, serves as a primary driver. Bioreactors provide the essential controlled environment for cultivating living cells that produce these biologic compounds, ensuring high product yield and quality.
   
• Additionally, the growing emphasis on personalized medicine and the development of targeted therapies significantly drives the market. As these therapies often require smaller, specialized production runs, biopharma manufacturers are investing in flexible bioreactor systems that can quickly adapt to different production scales and processes.
   

U.S. Bioreactors Market Share

The U.S. bioreactor sector is competitive, featuring a mix of major and smaller to medium-sized companies vying for market share. A pivotal aspect of market strategy involves the continual introduction of innovations such as automation and process control, integrated sensors and analytics, high-density cell cultures, and hybrid U.S. bioreactors. Notably, prominent industry players wield significant influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers play a crucial role in strengthening market positions and expanding footprints amid evolving regulatory landscapes.
 

U.S. Bioreactors Market Companies

Some of the eminent market participants operating in the U.S. bioreactors industry include:

• Altrad Group
• BaiLun Biotechnology Co., Ltd
• Danaher Corporation
• Donaldson Company, Inc
• Eppendorf Group
• Esco Micro Pte. Ltd.
• GEA Group Aktiengesellschaft
• Getinge AB
• Merck KGaA
• PBS Biotech, Inc.
• Sartorius AG
• Thermo Fisher Scientific Inc.
   

U.S. Bioreactors Industry News:

• In December 2022, Merck KGaA, a leading science and technology company, announced that it had acquired Erbi Biosystems, a Massachusetts-based developer of the 2 ml micro-bioreactor platform technology known as "Breez." This acquisition enhanced Merck KGaA's upstream portfolio in therapeutic proteins by enabling scalable cell-based perfusion bioreactor processes ranging from 2 ml to 2000 L, with rapid lab-scale process development. This move marked a significant step forward in Merck KGaA's efforts to expand its capabilities in therapeutic protein production.
   
• In August 2023, Sartorius AG and Repligen Corporation jointly unveiled an innovative bioreactor system. This system seamlessly integrated Repligen Corporation's XCell ATF upstream intensification technology into Sartorius AG's Biostat STR bioreactor. This strategic partnership underscored both companies' shared commitment to advancing the development of cutting-edge therapies and making medicine more accessible through collaborative expertise.
   

The U.S. bioreactors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million and volume in Units from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Single-use
  • Size
    • Less than 500 L
    • 501-5,000 L
    • More than 5,000 L 
• Reusable
  • Size
    • Less than 500 L
    • 501-5,000 L
    • More than 5,000 L
  • Material
    • Stainless steel
    • Glass

Market, By Cell

• Mammalian cells
• Bacterial cells
• Yeast cells
• Other cells

Market, By Molecule

• Monoclonal antibodies
• Vaccines
• Recombinant proteins
• Stem cells
• Gene therapy
• Other molecules

Market, By Usage

• Developmental, pre-clinical & clinical
• Commercial production

Market, By Material

• Stainless steel
  • Size
    • Less than 500 L
    • 501-5,000 L
    • More than 5,000 L 
• Glass
• Single-use

Market, By Size

• Less than 500 L
  • Single-use
  • Reusable
    • Stainless Steel
    • Glass 
• 501-5,000 L
  • Single-use
  • Reusable
• More than 5,000 L
  • Stainless Steel
  • Single-Use

Market, By End-use

• R&D organizations
• Biopharma manufacturers
• Contract manufacturing organizations (CMOs)